Document Detail

Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.
MedLine Citation:
PMID:  21862211     Owner:  NLM     Status:  MEDLINE    
We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their potential prostate cancer (PCa) therapy. Upon HDAC inhibitors-treatment, LNCaP cell growth was suppressed, correlating with increased cellular prostatic acid phosphatase (cPAcP) expression, an authentic protein tyrosine phosphatase. In those cells, ErbB-2 was dephosphorylated, histone H3/H4 acetylation and methylation increased and cyclin proteins decreased. In PAcP shRNA-transfected C-81 cells, valproic acid (VPA) efficacy of growth suppression was diminished. Further, VPA pre-treatment enhanced androgen responsiveness of C-81, C4-2 and MDA PCa2b-AI cells. Thus, cPAcP expression is involved in growth suppression by HDAC inhibitors in PCa cells, and VPA pre-treatments increase androgen responsiveness.
Yu-Wei Chou; Nagendra K Chaturvedi; Shougiang Ouyang; Fen-Fen Lin; Dharam Kaushik; Jue Wang; Isaac Kim; Ming-Fong Lin
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2011-07-22
Journal Detail:
Title:  Cancer letters     Volume:  311     ISSN:  1872-7980     ISO Abbreviation:  Cancer Lett.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-09-29     Completed Date:  2011-11-08     Revised Date:  2014-09-12    
Medline Journal Info:
Nlm Unique ID:  7600053     Medline TA:  Cancer Lett     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  177-86     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology
Blotting, Northern
Blotting, Western
Cell Line, Tumor
Cell Proliferation / drug effects
Cell Separation
Flow Cytometry
Histone Deacetylase Inhibitors / pharmacology*
Prostatic Neoplasms / metabolism*
Protein Tyrosine Phosphatases / biosynthesis*
Receptor, erbB-2 / metabolism
Valproic Acid / pharmacology*
Grant Support
2R01CA88184/CA/NCI NIH HHS; R01 CA088184/CA/NCI NIH HHS; R01 CA088184-10/CA/NCI NIH HHS
Reg. No./Substance:
0/Antineoplastic Agents; 0/Histone Deacetylase Inhibitors; 614OI1Z5WI/Valproic Acid; EC, erbB-2; EC acid phosphatase; EC Tyrosine Phosphatases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence and incidence of dementia among 75-80-year-old community-dwelling elderly in different di...
Next Document:  Targeting the ceramide system in cancer.